Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_2
4
57%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

terminated114%
withdrawn114%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529
completedphase_1

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00471471
completedphase_2

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

NCT00880581
withdrawnphase_2

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

NCT00471159
terminatedphase_3

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

NCT00254904
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00490529Phase 2

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Completed
NCT00471471Phase 1

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed
NCT00880581Phase 2

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Completed
NCT00471159Phase 2

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Withdrawn
NCT00254904Phase 3

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

Terminated
NCT00043368Phase 2

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Completed
NCT00043420Phase 1

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7